<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><description>为您传递细胞治疗相关行业信息与技术进展，共同促进国内免疫治疗技术发展与行业繁荣。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 09 Feb 2021 21:02:07 +0800</pubDate><image><url>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</url><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>抗SARS-CoV-2中和抗体的临床进展</title><link>https://mp.weixin.qq.com/s/4ywTB2P2BVHW4vfrmACdUw</link><description></description><content:encoded><![CDATA[抗SARS-CoV-2中和抗体的临床进展]]></content:encoded><pubDate>Tue, 09 Feb 2021 18:51:53 +0800</pubDate></item><item><title>抗体药物动态-20210209</title><link>https://mp.weixin.qq.com/s/HrtVpXnIX7FUASBXeandmw</link><description></description><content:encoded><![CDATA[抗体药物动态-20210209]]></content:encoded><pubDate>Tue, 09 Feb 2021 18:51:53 +0800</pubDate></item><item><title>新冠检测，如何控制核酸污染</title><link>https://mp.weixin.qq.com/s/r04uizEZTu6SzSijjtWJRA</link><description></description><content:encoded><![CDATA[新冠检测，如何控制核酸污染]]></content:encoded><pubDate>Mon, 08 Feb 2021 18:29:09 +0800</pubDate></item><item><title>抗体药物动态-20210208</title><link>https://mp.weixin.qq.com/s/NaNU9c_jIbZOkgmjamKUwA</link><description></description><content:encoded><![CDATA[抗体药物动态-20210208]]></content:encoded><pubDate>Mon, 08 Feb 2021 18:29:09 +0800</pubDate></item><item><title>Chugai制药神来之笔：肿瘤微环境抗体定向技术</title><link>https://mp.weixin.qq.com/s/tQMC3y4jGCcEyukTK9tMuA</link><description></description><content:encoded><![CDATA[Chugai制药神来之笔：肿瘤微环境抗体定向技术]]></content:encoded><pubDate>Sun, 07 Feb 2021 18:12:23 +0800</pubDate></item><item><title>抗体药物动态-20210207</title><link>https://mp.weixin.qq.com/s/LRaItgFko1k-rdR5lPjjOw</link><description></description><content:encoded><![CDATA[抗体药物动态-20210207]]></content:encoded><pubDate>Sun, 07 Feb 2021 18:12:23 +0800</pubDate></item><item><title>盘点：2020年全球CAR-T细胞领域研究进展TOP 10</title><link>https://mp.weixin.qq.com/s/f7fHXLoywqZBXwIOg8S-0Q</link><description></description><content:encoded><![CDATA[盘点：2020年全球CAR-T细胞领域研究进展TOP 10]]></content:encoded><pubDate>Fri, 05 Feb 2021 17:32:15 +0800</pubDate></item><item><title>2021年最值得关注的抗体药物</title><link>https://mp.weixin.qq.com/s/ENPh2m_Nn1xRCy0C-iu46g</link><description></description><content:encoded><![CDATA[2021年最值得关注的抗体药物]]></content:encoded><pubDate>Thu, 04 Feb 2021 18:34:39 +0800</pubDate></item><item><title>抗体药物动态-20210204</title><link>https://mp.weixin.qq.com/s/E1LtK_WScK6djer4rUFzog</link><description></description><content:encoded><![CDATA[抗体药物动态-20210204]]></content:encoded><pubDate>Thu, 04 Feb 2021 18:34:39 +0800</pubDate></item><item><title>IL-36：炎症与肿瘤</title><link>https://mp.weixin.qq.com/s/mE0LD5IEqVd4mFkNT9ThNA</link><description></description><content:encoded><![CDATA[IL-36：炎症与肿瘤]]></content:encoded><pubDate>Wed, 03 Feb 2021 19:08:42 +0800</pubDate></item><item><title>抗体+PROTAC的星星之火是否会有燎原之势？</title><link>https://mp.weixin.qq.com/s/CAM76d4Bi-AUOeCWLcMKww</link><description></description><content:encoded><![CDATA[抗体+PROTAC的星星之火是否会有燎原之势？]]></content:encoded><pubDate>Wed, 03 Feb 2021 19:08:42 +0800</pubDate></item><item><title>肿瘤干细胞与免疫细胞的相互作用</title><link>https://mp.weixin.qq.com/s/ekVzDlZKm3jm-PPYRwFPVA</link><description></description><content:encoded><![CDATA[肿瘤干细胞与免疫细胞的相互作用]]></content:encoded><pubDate>Tue, 02 Feb 2021 18:50:20 +0800</pubDate></item><item><title>抗体药物动态-20210202</title><link>https://mp.weixin.qq.com/s/MoFxYDaAYcIdb1oDg-IP2A</link><description></description><content:encoded><![CDATA[抗体药物动态-20210202]]></content:encoded><pubDate>Tue, 02 Feb 2021 18:50:20 +0800</pubDate></item><item><title>CD33靶向双特异性抗体的开发现状</title><link>https://mp.weixin.qq.com/s/L53S9jyPDMlnO9bYKQrwfQ</link><description></description><content:encoded><![CDATA[CD33靶向双特异性抗体的开发现状]]></content:encoded><pubDate>Mon, 01 Feb 2021 18:04:24 +0800</pubDate></item><item><title>抗体药物动态-20210201</title><link>https://mp.weixin.qq.com/s/zFb-mgezQgrBiJBtz9cCpQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210201]]></content:encoded><pubDate>Mon, 01 Feb 2021 18:04:24 +0800</pubDate></item><item><title>抗体药物动态-20210129</title><link>https://mp.weixin.qq.com/s/jHGxwAUJHHu1V_qAtmt_oQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210129]]></content:encoded><pubDate>Fri, 29 Jan 2021 18:56:48 +0800</pubDate></item><item><title>常见非IgG样双抗</title><link>https://mp.weixin.qq.com/s/-AFCnGiU4lLjNossw7Xlfg</link><description></description><content:encoded><![CDATA[常见非IgG样双抗]]></content:encoded><pubDate>Thu, 28 Jan 2021 18:11:02 +0800</pubDate></item><item><title>抗体药物动态-20210128</title><link>https://mp.weixin.qq.com/s/v1qFjVFLzHsa_vNQdoF2VA</link><description></description><content:encoded><![CDATA[抗体药物动态-20210128]]></content:encoded><pubDate>Thu, 28 Jan 2021 18:11:02 +0800</pubDate></item></channel></rss>